Research & development, technologies and products
We develop, produce and market vaccines and antibodies against a range of infectious diseases, focusing strongly–but not exclusively–on unmet medical needs in developing countries and emerging economies. Vaccines play a vital role in protecting against diseases and have contributed significantly to the improvement of global public health in the 21st century. Below we highlight Crucell’s key innovations.
-
€358.0 mln
Total revenues and operating income Products continue to show strong growth.
-
115+ mln
Vaccine doses distributed in 2009.
-
100 countries
Crucell vaccines were sold in more than 100 countries in 2009.
| Development stage | Research/ Pre-clinical | Phase I | Phase II | Phase III | Marketed | Description |
|---|---|---|---|---|---|---|
| Marketed products: | ||||||
| Quinvaxem® |  |
 |
 |
 |
 |
Fully liquid vaccine for protection against five childhood diseases. |
| Hepavax-Gene® | |
|
|
|
|
Recombinant hepatitis B vaccine. |
| Epaxal® Junior | |
|
|
|
|
Low dosage aluminum-free hepatitis A vaccine (0.25ml). |
| MoRu-Viraten® | |
|
|
|
|
Vaccine for protection against measles and rubella. |
| Epaxal® | |
|
|
|
|
Aluminum-free hepatitis A vaccine. |
| Vivotif® | |
|
|
|
|
Oral typhoid vaccine. |
| Dukoral® | |
|
|
|
|
Only internationally licensed oral vaccine against cholera (and ETEC). |
| Inflexal® V | |
|
|
|
|
Virosomal adjuvanted influenza vaccine. |
| Vaccines in development: | ||||||
| Flavimun® |  |
 |
 |
 |
Yellow fever vaccine. | |
| Influenza seasonal (flu cell) |
|
|
|
Seasonal influenza vaccine.1 | ||
| Tuberculosis | |
|
|
Recombinant AdVac®-based tuberculosis vaccine.2 | ||
| Malaria | |
|
Recombinant AdVac®-based malaria vaccine.3 | |||
| Ebola and Marburg | |
|
Recombinant AdVac®-based Ebola and Marburg vaccine.3 | |||
| HIV | |
|
Recombinant AdVac®-based vaccine.4 | |||
| Human monoclonal antibodies in development: | ||||||
| Rabies antibody combination |  |
 |
 |
Two human monoclonal antibodies for post-exposure treatment of rabies.5 | ||
| Influenza antibodies | |
Neutralizing antibody cross reactive against different influenza subtypes including H5 and H1. | ||||
| Hepatitis C antibody combination | |
Neutralizing monoclonal antibodies across all genotypes tested. | ||||
- 1
- Developed by sanofi pasteur using PER.C6®. 2 Partnered with Aeras. 3 Partnered with NIH/NIAID. 4 Partnered with Harvard.
- 5
- Partnered with sanofi pasteur.